"Ranibizumab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A recombinant humanized monoclonal antibody fragment that binds VEGF-A to prevent its binding to VEGFR-1 and VEGFR-2 receptors. This activity reduces vessel permeability and angiogenesis in the treatment of neovascular age-related MACULAR DEGENERATION.
| Descriptor ID |
D000069579
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.060.868 D12.776.124.790.651.114.224.060.868 D12.776.377.715.548.114.224.200.868
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ranibizumab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Ranibizumab [D12.776.124.486.485.114.224.060.868]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Ranibizumab [D12.776.124.790.651.114.224.060.868]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Ranibizumab [D12.776.377.715.548.114.224.200.868]
Below are MeSH descriptors whose meaning is more specific than "Ranibizumab".
This graph shows the total number of publications written about "Ranibizumab" by people in this website by year, and whether "Ranibizumab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 6 | 6 |
| 2015 | 1 | 3 | 4 |
| 2016 | 3 | 1 | 4 |
| 2017 | 3 | 3 | 6 |
| 2018 | 4 | 5 | 9 |
| 2019 | 2 | 5 | 7 |
| 2020 | 3 | 1 | 4 |
| 2021 | 4 | 5 | 9 |
| 2022 | 1 | 5 | 6 |
| 2023 | 4 | 6 | 10 |
| 2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ranibizumab" by people in Profiles.
-
Anti-VEGF Pharmaceutical Prior Authorization in Retina Practices. JAMA Ophthalmol. 2024 Aug 01; 142(8):716-721.
-
Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study. Lancet. 2024 04 20; 403(10436):1563-1573.
-
Morphological Biomarkers Related to Visual Acuity in Patients With Radiation Retinopathy Treated With Intravitreal Ranibizumab. Ophthalmic Surg Lasers Imaging Retina. 2024 May; 55(5):255-262.
-
Optimizing Visual Outcomes in Patients With Neovascular Age-Related Macular Degeneration: the Potential Value of Sustained Anti-VEGF Therapy. Ophthalmic Surg Lasers Imaging Retina. 2023 Nov; 54(11):654-659.
-
Subthreshold Compared with Threshold Macular Photocoagulation for Diabetic Macular Edema: A Systematic Review and Meta-Analysis. Ophthalmol Retina. 2024 Mar; 8(3):223-233.
-
Systemic Adverse Events Among Patients With Diabetes Treated With Intravitreal Anti-Vascular Endothelial Growth Factor Injections. JAMA Ophthalmol. 2023 07 01; 141(7):658-666.
-
Systematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment. BMJ Open Ophthalmol. 2023 06; 8(1).
-
Randomized Trial of Treat-and-Extend Intravitreal Aflibercept for Radiation Retinopathy: 1-Year Outcomes. Invest Ophthalmol Vis Sci. 2023 Jun 01; 64(7):35.
-
Safety of recent ophthalmic drugs and devices for wet macular degeneration. Curr Opin Ophthalmol. 2023 Sep 01; 34(5):363-368.
-
Anti-vascular endothelial growth factor therapy and retinal non-perfusion in diabetic retinopathy: A meta-analysis of randomised trials. Acta Ophthalmol. 2024 Feb; 102(1):e31-e41.